Login to Your Account

Company Optimistic; Analysts Skeptical

Adventrx Stock Falls 79% On CoFactor Trial Failure

By Trista Morrison

Tuesday, October 2, 2007
The first clinical trial to directly compare Adventrx Pharmaceuticals Inc.'s CoFactor (ANX-510) to leucovorin missed its primary endpoint of reducing serious hematological or gastrointestinal adverse events associated with the chemotherapy drug 5-fluorouracil (5-FU).(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription